Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00123487
Registration number
NCT00123487
Ethics application status
Date submitted
21/07/2005
Date registered
25/07/2005
Date last updated
2/11/2014
Titles & IDs
Public title
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Query!
Scientific title
A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Query!
Secondary ID [1]
0
0
CA180-035
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myeloid Leukemia, Chronic, Accelerated Phase
0
0
Query!
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - dasatinib
Treatment: Drugs - dasatinib
Experimental: dasatinib Twice a Day (BID) - 70 mg dasatinib twice a day (BID)
Experimental: dasatinib Once a Day (QD) - 140 mg dasatinib once a day (QD)
Treatment: Drugs: dasatinib
Tablets, Oral, 70 mg BID, indefinitely, survival study
Treatment: Drugs: dasatinib
Tablets, Oral, 140 mg QD, indefinitely, survival study
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population
Query!
Assessment method [1]
0
0
MaHR defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) = upper limit of normal (ULN); absolute neutrophil count (ANC) = 1,000/mm\^3; platelets = 100,000/mm\^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts = 5%; \<5% myelocytes plus metamyelocytes in PB; basophils in PB \< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets = 20,000/mm\^3 and \< 100,000/mm\^3; ANC \> 500/mm\^3 and \<1,000/mm\^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percentage: number of participants with MaHR/number of randomized participants.
Query!
Timepoint [1]
0
0
Randomization up to 6 months
Query!
Secondary outcome [1]
0
0
Percent of Participants With Major Hematological Response (MaHR) With 2 Years of Follow-up From Date of Last Enrollment - Randomized Population
Query!
Assessment method [1]
0
0
A MaHR was defined as a participant having either CHR or NEL. CHR was defined as: WBC = ULN; ANC = 1,000/mm\^3; - platelets = 100,000/mm\^3; - no blasts or promyelocytes in PB; BM blasts = 5%; \< 5% myelocytes plus metamyelocytes in PB; basophils in PB \< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (both lower limits had to be satisfied): platelets = 20,000/mm\^3 and \< 100,000/mm\^3; ANC \> 500/mm\^3 and \<1,000/mm\^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percent: number of participants with MaHR /number of participants randomized.
Query!
Timepoint [1]
0
0
Randomization up to 2 years
Query!
Secondary outcome [2]
0
0
Percent of Participants With Major Hematologic Response (MaHR) by Disease Group - Randomized Population
Query!
Assessment method [2]
0
0
MaHR was defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) = upper limit of normal (ULN); absolute neutrophil count (ANC) = 1,000/mm\^3; platelets = 100,000/mm\^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts = 5%; \<5% myelocytes plus metamyelocytes in PB; basophils in PB \< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one parameter of the following (note that both lower limits had to be satisfied): platelets = 20,000/mm\^3 and \< 100,000/mm\^3; ANC \> 500/mm\^3 and \<1,000/mm\^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule.. Percentage: participants with MaHR/randomized participants.
Query!
Timepoint [2]
0
0
Randomization up to 2 years
Query!
Secondary outcome [3]
0
0
Median Time to Major Hematologic Response (MaHR) - Randomized Population
Query!
Assessment method [3]
0
0
A participants' time to MaHR was defined as the time from the first dosing date until criteria are first met for CHR or NEL, whichever occurred first. Non-responders were censored at the maximum of the date of last hematologic or cytogenetic assessment. Median time was measured in months.
Query!
Timepoint [3]
0
0
Day 1 up to 6 months (time of primary endpoint), 2 years
Query!
Secondary outcome [4]
0
0
Median Duration of a Major Hematologic Response (MaHR) in Those Participants Who Achieved a MaHR During the Study
Query!
Assessment method [4]
0
0
MaHR was defined by either CHR or no evidence of leukemia NEL. CHR was defined as: WBC = ULN; ANC = 1,000/mm\^3; - platelets = 100,000/mm\^3; - no blasts or promyelocytes in PB; BM blasts = 5%; \< 5% myelocytes plus metamyelocytes in PB; basophils in PB \< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets = 20,000/mm\^3 and \< 100,000/mm\^3; ANC \> 500/mm\^3 and \<1,000/mm\^3. Median duration was measured in months.
Query!
Timepoint [4]
0
0
Day 1 up to 5 years
Query!
Secondary outcome [5]
0
0
Percent of Participants With Overall Hematologic Response - Randomized Population
Query!
Assessment method [5]
0
0
Overall Hematologic Response (OHR) was defined as CHR, NEL or minor hematologic response (MiHR). CHR was defined as: WBC = ULN; ANC = 1,000/mm\^3; - platelets = 100,000/mm\^3; - no blasts or promyelocytes in PB; BM blasts = 5%; \< 5% myelocytes plus metamyelocytes in PB; basophils in PB \< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets = 20,000/mm\^3 and \< 100,000/mm\^3; ANC \> 500/mm\^3 and \<1,000/mm\^3. MiHR defined as: \< 15% blasts in BM and in PB; \< 30% blasts + promyelocytes in BM and PB; \< 20% basophils in PB; No extra-medullary disease other than spleen and liver. Percentage: participants with OHR/ randomized participants.
Query!
Timepoint [5]
0
0
Randomization up to 6 Months, 2 Years
Query!
Secondary outcome [6]
0
0
Number of Participants With Best Confirmed Hematologic Response, Major Hematologic Response (MaHR) and Overall Hematologic Response - Randomized Population
Query!
Assessment method [6]
0
0
Type of hematologic response: CHR defined as: WBC = ULN; ANC = 1,000/mm\^3; - platelets = 100,000/mm\^3; - no blasts or promyelocytes in PB; BM blasts = 5%; \< 5% myelocytes plus metamyelocytes in PB; basophils in PB \< 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by the same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets = 20,000/mm\^3 and \<100,000/mm\^3; ANC \> 500/mm\^3 and \<1,000/mm\^3. Minor Hematologic Response (MiHR): \<15% blasts in BM and in PB; \< 30% blasts + promyelocytes in BM and PB; \< 20% basophils in PB; No extra-medullary disease other than spleen and liver. Major hematologic response (MaHR ) was CHR or NEL. Overall hematologic response was CHR or NEL or MiHR.
Query!
Timepoint [6]
0
0
Randomization up to 6 months, 2 years
Query!
Secondary outcome [7]
0
0
Percent of Participants With Major Cytogenetic Response (MCyR) - Randomized Population
Query!
Assessment method [7]
0
0
Cytogenetic assessments were performed only for the first 2 years of study. CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): 1% to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: 36% to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: 66% to 95% Ph+ cells in metaphase in BM; No cytogenetic response: 96% to 100% Ph+ cells in metaphase in BM; Major cytogenetic response (MCyR) was defined as CCyR or PCyR. Percentage: number of participants with MCyR and denominator is number of randomized participants.
Query!
Timepoint [7]
0
0
Randomization up to 6 Months, 2 Years
Query!
Secondary outcome [8]
0
0
Number of Participants With Best Cytogenic Response (CyR) - Randomized Population
Query!
Assessment method [8]
0
0
Cytogenetic assessments were performed only for the first 2 years of study. CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): 1% to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: 36% to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: 66% to 95% Ph+ cells in metaphase in BM; No cytogenetic response: 96% to 100% Ph+ cells in metaphase in BM.
Query!
Timepoint [8]
0
0
Randomization up to 6 Months, 2 Years
Query!
Secondary outcome [9]
0
0
Median Progression Free Survival (PFS) - Randomized Population
Query!
Assessment method [9]
0
0
PFS was defined as: Time from randomization until any of the following: Progression of disease (per investigator), or death. For those with blast phase CML or Ph+ ALL, disease progression was: loss of OHR; no decrease from on-study baseline percent blasts in PB or BM on all assessments over a 4-week period after starting maximum dose; absolute increase of at least 50% in PB blast count over a 2-week period after starting maximum dose. For those with accelerated phase CML: the list above also included: Development of blast phase CML at any time after initiation of therapy and development of extra-medullary sites other than spleen or liver. Participants who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. Median duration was measured in months.
Query!
Timepoint [9]
0
0
Randomization up to 5 Years
Query!
Secondary outcome [10]
0
0
Median Overall Survival (OS) - Randomized Population
Query!
Assessment method [10]
0
0
OS was defined as time from randomization until date of death. Participants who had not died or who were lost to follow-up were censored on the last date on which the participant was known to be alive. Median duration was measured in months.
Query!
Timepoint [10]
0
0
Randomization up to 5 Years
Query!
Secondary outcome [11]
0
0
Progression Free Survival (PFS) and Overall Survival (OS) at 24, 36, 48, and 60 Months - Randomized Population
Query!
Assessment method [11]
0
0
PFS was defined as time from randomization until any of the following: Progression of disease (per investigator), or death. For those with blast phase CML or Ph+ ALL, disease progression was: loss of OHR; no decrease from on-study baseline percent blasts in PB or BM on all assessments over a 4-week period after starting maximum dose; absolute increase of at least 50% in PB blast count over a 2-week period after starting maximum dose. For those with accelerated phase CML: the list above also included: Development of blast phase CML at any time after initiation of therapy and development of extra-medullary sites other than spleen or liver. Participants who neither progressed nor died were censored on the date of their last cytogenetic or hematologic assessment. OS was defined as time from randomization until date of death. Participants who had not died or were lost to follow-up were censored on the last date they were known to be alive. Median duration was measured in months.
Query!
Timepoint [11]
0
0
24 months, 36 months, 48 months, 60 months
Query!
Secondary outcome [12]
0
0
Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation and Drug-related Fluid Retention AEs, up to Year 7 in Treated Participants
Query!
Assessment method [12]
0
0
With protocol Amendment 6, the duration of the study was extended for 2 additional years (7 years total) for participants who continued to have clinical benefit and no feasible alternate access to dasatinib. However, after Year 5 the requirement to follow participants for survival and to collect other efficacy data was removed from the protocol for the remainder of the study. Only AEs and SAEs were collected up to Year 7. On-study AEs and SAEs were graded by severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. The investigator AE terms were coded and grouped by preferred term and system organ class using the Medical Dictionary for Regulatory Activities (MedDRA), version 16.0.
Query!
Timepoint [12]
0
0
Day 1 to Year 7
Query!
Secondary outcome [13]
0
0
Number of Participants With Normal Baseline Versus Worst Grade 3/4 Hematology Laboratory Abnormalities up to Year 2 in Treated Participants
Query!
Assessment method [13]
0
0
Laboratory abnormalities were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) version 3.0. CTC Grade 3 and 4 criteria are defined as follows: White blood cells (WBC): Grade (Gr) 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L. Absolute neutrophil count (ANC): Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L. Platelet count Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0 to 10\^9/L. Hemoglobin Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL. Baseline was laboratory value obtained within 2 weeks prior to randomization.
Query!
Timepoint [13]
0
0
Baseline to Year 2
Query!
Secondary outcome [14]
0
0
Number of Participants With Grade 4 Myelosuppression Determined From Hematology Evaluations
Query!
Assessment method [14]
0
0
Laboratory abnormalities were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0. Grade 4 hematology evaluations used to determine myelosuppression included: WBC: \<1.0\*10\^9/L. ANC: \<0.5\*10\^9/L. Platelet count \<25.0 to 10\^9/L.
Query!
Timepoint [14]
0
0
Day 1 up to Year 7
Query!
Secondary outcome [15]
0
0
Number of Participants With Normal Baseline Versus Worst Grade 3/4 Biochemistry Laboratory Abnormalities up to Year 2 in Treated Participants
Query!
Assessment method [15]
0
0
Laboratory abnormalities were graded according to the NCI CTC version 3.0. Grade 3 and 4 criteria were defined as follows: Upper limit of normal (ULN). Alanine transaminase (ALT) Grade (Gr) 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Aspartate aminotransferase (AST) Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Total bilirubin Gr 3: \>3.0 to 10..0\*ULN; Gr 4: \>10.0.0\*ULN. Serum creatinine (H) Gr 3: \>3.0 to 6.0\*ULN; Gr 4: \>6.0\*ULN. Calcium (L) Gr3: 6.0-7.0; Gr 4: \<6.0 mg/dL; Phosphorus (L): Gr 3: \<2.0 - 1.0 mg/dL , Gr 4: \<1.0 mg/dL. Non-hematologic laboratory results were not collected beyond Year 2. Baseline values were obtained within 2 weeks prior to randomization.
Query!
Timepoint [15]
0
0
Baseline to Year 2
Query!
Secondary outcome [16]
0
0
Number of Participants With Changes From Baseline in QT Interval Corrected With Fridericia Formula (QTcF) up to Year 2 in Treated Participants
Query!
Assessment method [16]
0
0
A12-lead electrocardiogram (ECG) was obtained at baseline (baseline=within 2 weeks prior to randomization) and once between Days 8 and 29. Additional ECGs were done at the Investigator's discretion. ECGs were read centrally. The QT interval corrected with Fridericia formula is presented with categories of changes from baseline (BL) in milliseconds (msec).
Query!
Timepoint [16]
0
0
Baseline to Year 2
Query!
Secondary outcome [17]
0
0
Number of Participants With Maximal QTcF Intervals up to Year 2 in Treated Participants
Query!
Assessment method [17]
0
0
A12-lead ECG was obtained at baseline (baseline=within 2 weeks prior to randomization) and once between Day 8 and 29. Additional ECGs were done at the Investigator's discretion. ECGs were read centrally. QT Interval corrected with Fridericia formula was measured in msec.
Query!
Timepoint [17]
0
0
Baseline up to Year 2
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
* Patients with Philadelphia-Positive (Ph+) (or BCR/ABL+) accelerated phase chronic myeloid leukemia, Ph+ (or BCR/ABL+) blast phase chronic myeloid leukemia, or Ph+ (or BCR/ABL+) acute lymphoblastic leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate
* Men and women, 18 years of age or older
* Adequate hepatic function
* Adequate renal function
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized
* Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Women who are pregnant or breastfeeding
* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
* Uncontrolled or significant cardiovascular disease
* Medications that increase bleeding risk
* Medications that change heart rhythms
* Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
* History of significant bleeding disorder unrelated to CML
* Concurrent incurable malignancy other than CML
* Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy
* Prior therapy with BMS-35425
* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
638
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - St Leonards
Query!
Recruitment hospital [2]
0
0
Local Institution - South Brisbane
Query!
Recruitment hospital [3]
0
0
Local Institution - Adelaide
Query!
Recruitment hospital [4]
0
0
Local Institution - Parkville
Query!
Recruitment hospital [5]
0
0
Local Institution - Perth
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
SA 5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [5]
0
0
WA 6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oregon
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Buenos Aires
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Wien
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
B-leuven
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Brugge
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Bruxelles
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Charleroi
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Yvoir
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Parana
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Sao Paulo
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Rio De Janeiro
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Alberta
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
British Columbia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Czech Republic
Query!
State/province [36]
0
0
Brno
Query!
Country [37]
0
0
Czech Republic
Query!
State/province [37]
0
0
Prague 2
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Aarhus C
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Herlev
Query!
Country [40]
0
0
Denmark
Query!
State/province [40]
0
0
Odense C
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Helsinki
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Caen Cedex
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Creteil Cedex
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Grenoble Cedex 9
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Lille Cedex
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Lyon Cedex
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Marseille Cedex 9
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Nantes
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Paris Cedex 10
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Pessac
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Poitiers Cedex
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Strasbourg Cedex
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Dresden
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Frankfurt
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Hamburg
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Leipzig
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Mainz
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Mannheim
Query!
Country [59]
0
0
Greece
Query!
State/province [59]
0
0
Athens
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Budapest
Query!
Country [61]
0
0
Ireland
Query!
State/province [61]
0
0
Dublin
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Ramat-gan
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Bari
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Bologna
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Monza
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Napoli
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Orbassano (to)
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Roma
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Jeollanam-do
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Seoul
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Rotterdam
Query!
Country [72]
0
0
Norway
Query!
State/province [72]
0
0
Trondheim
Query!
Country [73]
0
0
Peru
Query!
State/province [73]
0
0
Lima
Query!
Country [74]
0
0
Philippines
Query!
State/province [74]
0
0
Quezon City
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Gdansk
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Katowice
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Krakow
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Lodz
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Lublin
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Warsaw
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Moscow
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
St.petersburg
Query!
Country [83]
0
0
Singapore
Query!
State/province [83]
0
0
Singapore
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Free State
Query!
Country [85]
0
0
South Africa
Query!
State/province [85]
0
0
Gauteng
Query!
Country [86]
0
0
South Africa
Query!
State/province [86]
0
0
Western Cape
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Barcelona
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Madrid
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Valencia
Query!
Country [90]
0
0
Sweden
Query!
State/province [90]
0
0
Lund
Query!
Country [91]
0
0
Sweden
Query!
State/province [91]
0
0
Stockholm
Query!
Country [92]
0
0
Sweden
Query!
State/province [92]
0
0
Umea
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Uppsala
Query!
Country [94]
0
0
Switzerland
Query!
State/province [94]
0
0
Basel
Query!
Country [95]
0
0
Taiwan
Query!
State/province [95]
0
0
Taipei
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taoyuan
Query!
Country [97]
0
0
Thailand
Query!
State/province [97]
0
0
Bangkok
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Greater London
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Scotland
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Tyne And Wear
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Edinburgh
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Liverpool
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).
Query!
Trial website
https://clinicaltrials.gov/study/NCT00123487
Query!
Trial related presentations / publications
Chu SC, Tang JL, Li CC. Dasatinib in chronic myelogenous leukemia. N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4. No abstract available. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Muller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar;85(3):164-70. doi: 10.1002/ajh.21615. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Muller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9. doi: 10.1182/blood-2008-11-186817. Epub 2009 Apr 15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Chu SC, Tang JL, Li CC. Dasatinib in chronic myelo...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00123487
Download to PDF